EP3177322A4 - Anticorps anti-trem2 et leurs procédés d'utilisation - Google Patents

Anticorps anti-trem2 et leurs procédés d'utilisation Download PDF

Info

Publication number
EP3177322A4
EP3177322A4 EP15830235.6A EP15830235A EP3177322A4 EP 3177322 A4 EP3177322 A4 EP 3177322A4 EP 15830235 A EP15830235 A EP 15830235A EP 3177322 A4 EP3177322 A4 EP 3177322A4
Authority
EP
European Patent Office
Prior art keywords
methods
trem2 antibodies
trem2
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP15830235.6A
Other languages
German (de)
English (en)
Other versions
EP3177322A2 (fr
Inventor
Kate MONROE
Tina SCHWABE
Francesca Avogadri-Connors
Ilaria TASSI
Helen LAM
Arnon Rosenthal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alector LLC
Original Assignee
Alector LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55264791&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3177322(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alector LLC filed Critical Alector LLC
Priority to EP21189092.6A priority Critical patent/EP4066859A1/fr
Publication of EP3177322A2 publication Critical patent/EP3177322A2/fr
Publication of EP3177322A4 publication Critical patent/EP3177322A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
EP15830235.6A 2014-08-08 2015-08-08 Anticorps anti-trem2 et leurs procédés d'utilisation Ceased EP3177322A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP21189092.6A EP4066859A1 (fr) 2014-08-08 2015-08-08 Anticorps anti-trem2 et leurs procédés d'utilisation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462035336P 2014-08-08 2014-08-08
US201562135122P 2015-03-18 2015-03-18
US201562135110P 2015-03-18 2015-03-18
PCT/US2015/044396 WO2016023019A2 (fr) 2014-08-08 2015-08-08 Anticorps anti-trem2 et leurs procédés d'utilisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP21189092.6A Division EP4066859A1 (fr) 2014-08-08 2015-08-08 Anticorps anti-trem2 et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
EP3177322A2 EP3177322A2 (fr) 2017-06-14
EP3177322A4 true EP3177322A4 (fr) 2018-07-18

Family

ID=55264791

Family Applications (2)

Application Number Title Priority Date Filing Date
EP21189092.6A Pending EP4066859A1 (fr) 2014-08-08 2015-08-08 Anticorps anti-trem2 et leurs procédés d'utilisation
EP15830235.6A Ceased EP3177322A4 (fr) 2014-08-08 2015-08-08 Anticorps anti-trem2 et leurs procédés d'utilisation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP21189092.6A Pending EP4066859A1 (fr) 2014-08-08 2015-08-08 Anticorps anti-trem2 et leurs procédés d'utilisation

Country Status (12)

Country Link
US (4) US20170240631A1 (fr)
EP (2) EP4066859A1 (fr)
JP (3) JP6669749B2 (fr)
CN (1) CN107106679B (fr)
AU (2) AU2015300787A1 (fr)
CA (2) CA2955086A1 (fr)
EA (1) EA201790342A1 (fr)
HK (1) HK1243006A1 (fr)
IL (2) IL279606B (fr)
MX (2) MX2017001531A (fr)
SG (2) SG10201913611QA (fr)
WO (1) WO2016023019A2 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913611QA (en) 2014-08-08 2020-03-30 Alector Llc Anti-trem2 antibodies and methods of use thereof
KR20240056629A (ko) * 2014-09-28 2024-04-30 더 리전트 오브 더 유니버시티 오브 캘리포니아 자극성 및 비자극성 골수성 세포의 조절
WO2017058866A1 (fr) * 2015-09-28 2017-04-06 Precision Immune, Inc. Anticorps anti-trem2 et leurs utilisations
KR20180068999A (ko) * 2015-10-06 2018-06-22 알렉터 엘엘씨 항-trem2 항체 및 그의 사용방법
AR107505A1 (es) 2016-01-22 2018-05-09 Merck Sharp & Dohme Anticuerpos anti-factor de la coagulación xi
TN2018000417A1 (en) 2016-06-14 2020-06-15 Adimab Llc Anti-coagulation factor xi antibodies.
EP3487886A2 (fr) 2016-07-22 2019-05-29 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Modulateurs du clivage de trem2 et leurs utilisations
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
CN108727489B (zh) * 2017-04-19 2021-02-09 广州市第八人民医院 一种单克隆抗体zk2c2及应用
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
EP3625258A1 (fr) 2017-05-16 2020-03-25 Alector LLC Anticorps anti-siglec-5 et leurs procédés d'utilisation
WO2019014667A1 (fr) 2017-07-14 2019-01-17 The Regents Of The University Of California Nouveaux procédés de prédiction du risque de rejet de greffe
BR112019022752A2 (pt) 2017-08-03 2020-05-19 Alector Llc anticorpos anti-trem2 e métodos de uso dos mesmos
CN111448212A (zh) * 2017-09-14 2020-07-24 戴纳立制药公司 抗trem2抗体及其使用方法
KR20220015499A (ko) * 2017-10-03 2022-02-08 프리베일 테라퓨틱스, 인크. 리소좀 장애를 위한 유전자 요법
CA3083660A1 (fr) * 2017-12-12 2019-06-20 Pionyr Immunotherapeutics, Inc. Anticorps anti-trem2 et methodes associees
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
EP3728323A4 (fr) * 2017-12-19 2022-01-26 Surrozen Operating, Inc. Anticorps anti-fzd et méthodes d'utilisation
EP3732201A4 (fr) * 2017-12-19 2022-04-20 Surrozen Operating, Inc. Molécules de substitution de wnt et leurs utilisations
CN111886246A (zh) * 2017-12-29 2020-11-03 艾莱克特有限责任公司 抗tmem106b抗体及其使用方法
CN112566934A (zh) * 2018-01-23 2021-03-26 奈斯科尔公司 B7-h4抗体及其使用方法
MA52753A (fr) 2018-05-25 2021-04-21 Alector Llc Anticorps anti-sirpa et leurs procédés d'utilisation
SG11202100555PA (en) * 2018-07-27 2021-02-25 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
MX2021002616A (es) * 2018-09-11 2021-05-12 Washington University St Louis Anticuerpos agonistas anti receptor desencadenante expresado en celulas mieloides 2 (trem-2).
UY38407A (es) * 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
KR102156165B1 (ko) * 2018-10-29 2020-09-15 재단법인대구경북과학기술원 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
MA54296A (fr) 2018-11-26 2021-10-06 Denali Therapeutics Inc Procédés de traitement du métabolisme lipidique dérégulé
WO2020121195A1 (fr) * 2018-12-10 2020-06-18 Mor Research Applications Anticorps trem2 et leurs utilisations
WO2020123664A1 (fr) * 2018-12-11 2020-06-18 Pionyr Immunotherapeutics, Inc. Méthodes d'utilisation d'anticorps anti-trem2
CN109646668B (zh) * 2019-01-04 2019-10-18 厦门大学 一种多肽用于制备防治阿尔茨海默病药物的用途
MA55025A (fr) * 2019-02-20 2021-12-29 Denali Therapeutics Inc Anticorps anti-trem2 et leurs procédés d'utilisation
WO2020194317A1 (fr) * 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Méthode de traitement de troubles liés aux lipides
CN110320368A (zh) * 2019-05-30 2019-10-11 广州医科大学附属第一医院（广州呼吸中心） 基于trem2的诊断试剂盒及其在帕金森病诊断产品上的应用
EP3994159A4 (fr) * 2019-07-05 2023-08-09 University of Florida Research Foundation, Incorporated Méthodes de traitement de maladies neurologiques associées à la protéine ran
JP2022540674A (ja) * 2019-07-15 2022-09-16 ブリストル－マイヤーズ スクイブ カンパニー 抗ｔｒｅｍ－１抗体およびその使用
EP4031178A1 (fr) * 2019-09-16 2022-07-27 Surface Oncology, Inc. Compositions d'anticorps anti-cd39 et procédés associés
EP4061842A1 (fr) 2019-11-22 2022-09-28 Eli Lilly and Company Anticorps trem2 et leurs utilisations
CN111000978B (zh) * 2019-11-22 2023-03-10 中山大学附属第五医院 Tlt-2在制备治疗结核病药物中的应用
BR112022013756A2 (pt) 2020-01-13 2022-10-11 Denali Therapeutics Inc Anticorpos anti-trem2 e métodos de uso dos mesmos
IL272390A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Cancer treatment methods
WO2021174003A2 (fr) * 2020-02-26 2021-09-02 Washington University Compositions et méthodes pour réduire la résistance à l'immunothérapie ou améliorer celle-ci
CA3190581A1 (fr) * 2020-08-05 2022-02-10 Vigil Neuroscience, Inc. Traitement de maladies associees au dysfonctionnement du recepteur de facteur 1 de stimulation des colonies au moyen d'agonistes de trem2
CN112526143B (zh) * 2020-12-03 2021-08-03 中山大学附属第五医院 髓系细胞触发受体2作为新型冠状病毒肺炎诊断或治疗靶点的应用
CN115109150A (zh) * 2021-01-31 2022-09-27 中南大学湘雅医院 新型冠状病毒单克隆抗体xy10及其应用
WO2023092146A1 (fr) * 2021-11-22 2023-05-25 Vigil Neuroscience, Inc. Anticorps anti-trem2 et ses utilisations
WO2023114499A1 (fr) 2021-12-17 2023-06-22 Denali Therapeutics Inc. Ingénierie polypeptidique, bibliothèques et polypeptides ingéniérisés de liaison de chaîne lourde cd98 et de récepteur de transferrine
JP7452918B2 (ja) 2021-12-22 2024-03-19 国立大学法人 鹿児島大学 マクロファージの製造方法、分化誘導剤、分化誘導キット、マクロファージの分化誘導方法、マクロファージの増殖促進剤、マクロファージの増殖促進キット、マクロファージの増殖方法及びマクロファージ
WO2023150724A2 (fr) * 2022-02-04 2023-08-10 Sorrento Therapeutics, Inc. Protéines de liaison à l'antigène qui se lient à b7-h3
WO2023159140A2 (fr) * 2022-02-17 2023-08-24 Adimab, Llc Polypeptides anti-asgr1 et méthodes d'utilisation pour tolérance immunitaire
CN114395034B (zh) * 2022-03-24 2022-08-05 中国科学院微生物研究所 一种高效中和新型冠状病毒的人源抗体及其应用
WO2023192282A1 (fr) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Méthodes de traitement de l'hypométabolisme du glucose cérébral
WO2023192288A1 (fr) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Molécules de liaison anti-trem2 monovalentes et leurs procédés d'utilisation
WO2024052343A1 (fr) 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Agonistes de trem-2 pour le traitement du syndrome de marfan

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
WO1991010741A1 (fr) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation d'anticorps xenogeniques
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1993006217A1 (fr) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION DANS L'E. COLI DE FRAGMENTS D'ANTICORPS POSSEDANT AU MOINS UNE CYSTEINE PRESENTE SOUS FORME D'UN THIOL LIBRE, ET LEUR UTILISATION DANS LA PRODUCTION D'ANTICORPS BIFONCTIONNELS F(ab')¿2?
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0656064B1 (fr) 1992-08-17 1997-03-05 Genentech, Inc. Immunoadhesines bispecifiques
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
CA2219361C (fr) 1995-04-27 2012-02-28 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
EP0823941A4 (fr) 1995-04-28 2001-09-19 Abgenix Inc Anticorps humains derives de xeno-souris immunisees
WO1997011971A1 (fr) 1995-09-28 1997-04-03 Alexion Pharmaceuticals, Inc. Proteines d'interaction de cellules porcines
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
EP1500329B1 (fr) 1996-12-03 2012-03-21 Amgen Fremont Inc. Les anticorps humains qui lient en particulier l'alpha de TNF humain
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
BR9813365A (pt) 1997-12-05 2004-06-15 Scripps Research Inst Método para produção e humanização de um anticorpo monoclonal de rato
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1090118A2 (fr) 1998-06-26 2001-04-11 Incyte Pharmaceuticals, Inc. Proteines contenant un peptide signal humain
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
WO2001025454A2 (fr) 1999-10-04 2001-04-12 Medicago Inc. Procede de regulation de la transcription de genes etrangers
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US20090081199A1 (en) 2001-03-20 2009-03-26 Bioxell S.P.A. Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
CA2342376C (fr) 2001-03-20 2013-11-12 Marco Colonna Nouveau recepteur trem (recepteur activateur exprime dans les cellules myeloides) et ses utilisations
WO2003099331A1 (fr) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited Agents renforçateurs de la résistance à l'insuline
JP2004073182A (ja) 2002-05-24 2004-03-11 Takeda Chem Ind Ltd インスリン抵抗性改善剤
JP2006504971A (ja) 2002-11-01 2006-02-09 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト マトリックス支援レーザー脱離イオン化−飛行時間型質量分析によるタンパク質アイソフォームの定量的解析
EP1578367A4 (fr) 2002-11-01 2012-05-02 Genentech Inc Compositions et methodes pour le traitement de maladies liees au systeme immunitaire
WO2004074506A2 (fr) 2003-02-13 2004-09-02 Mergen Ltd Sequences polynucleotidiques et polypeptides codes correspondants de proteines specifiques secretees et liees a la membrane sur-exprimees dans certains cancers
AU2005323025A1 (en) 2004-12-31 2006-07-13 Biogen Idec Ma Inc. Polypeptides that bind BR3 and uses thereof
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
DK2359834T5 (en) 2006-03-15 2017-02-06 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
US8093360B2 (en) 2006-09-28 2012-01-10 Elusys Therapeutics, Inc. Antibodies that bind B. anthracis exotoxin, formulations thereof, and methods of use
US7673853B2 (en) 2006-10-12 2010-03-09 Cordell Eldred Ebeling Fencing section with adjustable fencing members
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
BRPI0816785A2 (pt) 2007-09-14 2017-05-02 Adimab Inc bibliotecas de anticorpos sintéticos racionalmente desenhadas, e, usos para as mesmas
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2186928A1 (fr) 2008-11-14 2010-05-19 Enthone, Inc. Procédé pour le post-traitement des couches métalliques
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
MX360336B (es) 2010-07-16 2018-10-30 Adimab Llc Star Colecciones de anticuerpos.
US20130015055A1 (en) * 2011-07-11 2013-01-17 Hariharakeshava Sarpangala Hegde Dual plasma source systems and methods for reactive plasma deposition
WO2014074942A1 (fr) * 2012-11-08 2014-05-15 Illumina, Inc. Variants de risque de développer la maladie d'alzheimer
SG10201913611QA (en) 2014-08-08 2020-03-30 Alector Llc Anti-trem2 antibodies and methods of use thereof
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
KR20240056629A (ko) 2014-09-28 2024-04-30 더 리전트 오브 더 유니버시티 오브 캘리포니아 자극성 및 비자극성 골수성 세포의 조절
WO2016064895A1 (fr) 2014-10-20 2016-04-28 The Brigham And Women's Hospital, Inc. Ciblage de l'apolipoprotéine e (apoe) dans une maladie neurologique
WO2017058866A1 (fr) 2015-09-28 2017-04-06 Precision Immune, Inc. Anticorps anti-trem2 et leurs utilisations
KR20180068999A (ko) 2015-10-06 2018-06-22 알렉터 엘엘씨 항-trem2 항체 및 그의 사용방법
EP3487886A2 (fr) 2016-07-22 2019-05-29 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Modulateurs du clivage de trem2 et leurs utilisations
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
BR112019022752A2 (pt) 2017-08-03 2020-05-19 Alector Llc anticorpos anti-trem2 e métodos de uso dos mesmos
CN111448212A (zh) 2017-09-14 2020-07-24 戴纳立制药公司 抗trem2抗体及其使用方法
CA3083660A1 (fr) 2017-12-12 2019-06-20 Pionyr Immunotherapeutics, Inc. Anticorps anti-trem2 et methodes associees

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COLONNA M: "TREMS IN THE IMMUNE SYSTEM AND BEYOND", THE JOURNAL OF IMMUNO, NATURE PUB. GROUP, GB, vol. 3, no. 6, 1 June 2003 (2003-06-01), pages 445 - 453, XP008055962, ISSN: 1474-1733, DOI: 10.1038/NRI1106 *
HIROAKI ITO ET AL: "TREM-2, triggering receptor expressed on myeloid cell-2, negatively regulates TLR responses in dendritic cells : Innate immunity", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 42, no. 1, 12 December 2011 (2011-12-12), pages 176 - 185, XP055454078, ISSN: 0014-2980, DOI: 10.1002/eji.201141679 *
MINGXIA SUN ET AL: "Immunology and Microbiology TREM-2 Promotes Host Resistance Against Pseudomonas aeruginosa Infection by Suppressing Corneal Inflammation via a PI3K/Akt Signaling Pathway", INVEST OPHTHALMOL VIS SCI, vol. 54, 1 May 2013 (2013-05-01), pages 3451 - 3462, XP055327576 *
Q. PENG ET AL: "TREM2- and DAP12-Dependent Activation of PI3K Requires DAP10 and Is Inhibited by SHIP1", SCIENCE SIGNALING, vol. 3, no. 122, 18 May 2010 (2010-05-18), pages ra38 - ra38, XP055338013, DOI: 10.1126/scisignal.2000500 *

Also Published As

Publication number Publication date
US20230107639A1 (en) 2023-04-06
CA2955086A1 (fr) 2016-02-11
MX2023000334A (es) 2023-02-09
WO2016023019A2 (fr) 2016-02-11
EA201790342A1 (ru) 2017-07-31
MX2017001531A (es) 2017-05-15
IL250115B (en) 2021-01-31
JP2022081543A (ja) 2022-05-31
JP7326135B2 (ja) 2023-08-15
US20190315858A1 (en) 2019-10-17
IL279606A (en) 2021-03-01
IL250115A0 (en) 2017-03-30
CN107106679B (zh) 2022-07-26
SG10201913611QA (en) 2020-03-30
US11084875B2 (en) 2021-08-10
WO2016023019A3 (fr) 2016-07-28
US20190010230A1 (en) 2019-01-10
EP4066859A1 (fr) 2022-10-05
JP2017523814A (ja) 2017-08-24
CA3090240A1 (fr) 2016-02-11
AU2015300787A1 (en) 2017-02-02
CN107106679A (zh) 2017-08-29
US20170240631A1 (en) 2017-08-24
EP3177322A2 (fr) 2017-06-14
SG11201700901SA (en) 2017-03-30
IL279606B (en) 2022-08-01
JP2020063268A (ja) 2020-04-23
JP6669749B2 (ja) 2020-03-18
AU2021202840A1 (en) 2021-06-03
HK1243006A1 (zh) 2018-07-06

Similar Documents

Publication Publication Date Title
IL279606A (en) Anti-TREM2 antibodies and methods of using them
HK1243102A1 (zh) 抗cd79b抗體和使用方法
EP3383430A4 (fr) Anticorps et leurs méthodes d'utilisation
HRP20181359T1 (hr) Anti-jagged1 protutijela i postupci uporabe
IL251868B (en) Anti-tim3 antibodies and methods of use
EP3280441A4 (fr) Anticorps anti-sortiline et leurs méthodes d'utilisation
EP3230319B8 (fr) Anticorps dirigés contre la protéine de mort programmée 1 (pd-1)
EP3233921A4 (fr) Anticorps anti-c5 et leurs procédés d'utilisation
EP3116911B8 (fr) Anticorps anti-mcam et procédés d'utilisation associés
EP3383917A4 (fr) Nouveaux anticorps anti-claudine et méthodes d'utilisation
IL251165A0 (en) Anti-il-1beta antibodies and methods of their use
EP3134121A4 (fr) Nouveaux anticorps anti-rnf43 et méthodes d'utilisation
EP3189079A4 (fr) Nouveaux anticorps anti-mfi2 et méthodes d'utilisation
IL251286A0 (en) Anti-pdgf-b antibodies and methods of use
AU2014901301A0 (en) PAT-SM3 related antibodies and methods of making and using same

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170224

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101ALI20180228BHEP

Ipc: A61K 39/395 20060101AFI20180228BHEP

Ipc: A61K 39/00 20060101ALI20180228BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20180618

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20180612BHEP

Ipc: C07K 16/28 20060101ALI20180612BHEP

Ipc: A61K 39/395 20060101AFI20180612BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190219

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20210322